Evidence map›Paper›PMID 35000083›Full record

ArticleAnnals of surgical oncology2022

Circulating Tumor Cell Transcriptomics as Biopsy Surrogates in Metastatic Breast Cancer.

Alexander Ring, Daniel Campo, Tania B Porras, Pushpinder Kaur, Victoria A Forte, Debu Tripathy, Janice Lu, Irene Kang, Michael F Press, Young Ju Jeong and 5 more

Erratum issuedOpen access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of surgical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 3 countries.

Alexander RingDivision of Surgical Oncology, Department of Surgery and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA.
Daniel CampoDepartment of Biological Sciences, University of Southern California, Los Angeles, CA, USA.
Tania B PorrasDivision of Surgical Oncology, Department of Surgery and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA.
Pushpinder KaurDivision of Surgical Oncology, Department of Surgery and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA.
Victoria A ForteDivision of Medical Oncology, Department of Medicine, SUNY Downstate Medical Center, New York, NY, USA.
Debu TripathyDepartment of Breast Medical Oncology, UT MD Anderson Cancer Center, Houston, TX, USA.
Janice LuDivision of Medical Oncology, Department of Medicine and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA.
Irene KangDepartment of Pathology and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA.
Michael F PressDepartment of Pathology and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA.
Young Ju JeongDepartment of Surgery, Catholic University of Daegu School of Medicine, Daegu, Republic of Korea.
Anson SnowDivision of Surgical Oncology, Department of Surgery and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA.
Yue ZhuDivision of Surgical Oncology, Department of Surgery and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA.
Gabriel ZadaDepartment of Neurosurgery and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA.
Naveed WagleDivision of Medical Oncology, Department of Medicine and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA.
Julie E LangDivision of Surgical Oncology, Department of Surgery and University of Southern California Norris Cancer Center, University of Southern California, Los Angeles, CA, USA. LANGJ2@ccf.org.
University of Southern California · USDaegu Catholic University · KRSUNY Downstate Health Sciences University · USThe University of Texas MD Anderson Cancer Center · US

Funding

USC/NORRIS COMPREHENSIVE CANCER CENTER (CORE) SUPPORTP30CA014089 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI William Dean Wallace · 1985 to 2026
$181.4M
Mentored Career DevelopmentKL2TR001854 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Elizabeth Rhea Erwin Burner, Amy Elizabeth West · 2016 to 2026
$9.0M
ANGLE plc. Personal grant to J.E.L.NCATS NIH HHS KL2 TR001854NCI NIH HHS P30 CA014089NCI NIH HHS P30CA014089
6 · The paper itself

Abstract

backgroundMetastatic breast cancer (MBC) and the circulating tumor cells (CTCs) leading to macrometastases are inherently different than primary breast cancer. We evaluated whether whole transcriptome RNA-Seq of CTCs isolated via an epitope-independent approach may serve as a surrogate for biopsies of macrometastases.

methodsWe performed RNA-Seq on fresh metastatic tumor biopsies, CTCs, and peripheral blood (PB) from 19 newly diagnosed MBC patients. CTCs were harvested using the ANGLE Parsortix microfluidics system to isolate cells based on size and deformability, independent of a priori knowledge of cell surface marker expression.

resultsGene expression separated CTCs, metastatic biopsies, and PB into distinct groups despite heterogeneity between patients and sample types. CTCs showed higher expression of immune oncology targets compared with corresponding metastases and PB. Predictive biomarker (n = 64) expression was highly concordant for CTCs and metastases. Repeat observation data post-treatment demonstrated changes in the activation of different biological pathways. Somatic single nucleotide variant analysis showed increasing mutational complexity over time.

conclusionWe demonstrate that RNA-Seq of CTCs could serve as a surrogate biomarker for breast cancer macrometastasis and yield clinically relevant insights into disease biology and clinically actionable targets.

Indexed as

Breast NeoplasmsNeoplastic Cells, CirculatingBiomarkers, TumorBiopsyFemaleHumansNeoplasm MetastasisTranscriptomeBiomarkers, Tumor

Identifiers

PMID35000083
PMCPMC8989945
OpenAlexW4206015960

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.